Ultragenyx Pharmaceutical Inc.
NASDAQ:RAREBiotechnology
+$0.81 today
- Market cap
- $1.81B
- Beta
- 0.38
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$6.06
Volume 5.16M
Average 1.81M
RARE Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Ultragenyx Pharmaceutical Inc.NASDAQ: RARE
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables growth accelerates
Q1 FY2026 accounts receivables of $19M rose 88.8% year over year, ahead of the -1708.0% change in trailing-twelve-month accounts receivables. Over 3 fiscal years it compounded at +37.0% a year.
Context
- Accounts receivables amounted to 4.6% of revenue in FY2025, down 1.4 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +88.8% holds above the trailing-twelve-month pace of -1708.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (31M) USD
- Year-over-year change
- +7.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31M) | +7.7% |
| FY2024 | 2024-12-31 | (33.6M) | -47.5% |
| FY2023 | 2023-12-31 | (22.78M) | -88.7% |
| FY2022 | 2022-12-31 | (12.07M) | -122.2% |
| FY2021 | 2021-12-31 | (5.43M) | — |
Accounts Receivables vs competitors
How RARE compares with its peers on the latest reported figures
- RARE's LTM Mar 2026 accounts receivables of $22.06M is the 4th largest of the 11 companies compared; the peer median is $3.47M.
- Its year-over-year change of -1708.0% is the lowest of 9, against a peer median of -1.2%.
- Accounts receivables amounts to 3.3% of revenue for RARE, versus a peer median of 10.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $60.56B | +173755.7% | +40.6% | 5.9% | |
| LTM Jun 2026 | $177.62M | +133.1% | — | 24.9% | |
| LTM Jun 2026 | $44.38M | -720.6% | -40.6% | 4.4% | |
| LTM Mar 2026 | $22.06M | -1708.0% | +37.0% | 3.3% | |
| LTM Mar 2026 | $13.03M | -178.8% | — | 16.3% | |
| LTM Mar 2026 | $9.02M | +328.9% | — | 10.3% | |
| LTM Mar 2026 | $5.09M | -985.6% | — | 35.0% | |
| LTM Mar 2026 | $1.84M | -135.4% | -44.0% | 10.2% | |
| LTM Mar 2026 | $345.69K | +257.1% | — | 69.1% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding RARE) | $3.47M | -1.2% | -40.6% | 10.3% | |
Competitors are the stored peer set for RARE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (454.03M) | (707.42M) | (606.64M) | (569.18M) | (575M) |
| Depreciation & Amortization | 13.24M | 18.22M | 26.01M | 35.54M | 35M |
| Deferred Income Tax | 48.67M | 0 | (1.62M) | 0 | 0 |
| Stock-Based Compensation | 104.95M | 130.38M | 135.21M | 158.03M | 153M |
| Change in Working Capital | (63.24M) | 60.24M | (15.1M) | 13.92M | (23M) |
| Accounts Receivables | (5.43M) | (12.07M) | (22.78M) | (33.6M) | (31M) |
| Inventory | (3.12M) | (9.7M) | (6.93M) | (11.21M) | (6M) |
| Accounts Payables | 2.81M | 79.85M | 2.38M | 46.99M | 24M |
| Other Working Capital | (57.49M) | 2.16M | 12.23M | 11.73M | (10M) |
| Other Non-Cash Items | 11.71M | 118.12M | (12.67M) | (52.5M) | (56M) |
| Operating Cash Flow | (338.7M) | (380.47M) | (474.81M) | (414.19M) | (466M) |
| Capital Expenditures | (73.09M) | (146.12M) | (46.77M) | (7.49M) | (6M) |
| Acquisitions (Net) | 0 | (75.03M) | 0 | 0 | 0 |
| Purchases of Investments | (1.01B) | (614.74M) | (526.38M) | (408.61M) | (186M) |
| Sales of Investments | 890.85M | 545.08M | 746.2M | 413.27M | 444M |
| Other Investing Activities | (942K) | (30.84M) | (7.55M) | (14.94M) | (16M) |
| Investing Cash Flow | (195.37M) | (291.65M) | 168M | (17.77M) | 236M |
| Debt Repayment | 0 | 0 | 0 | 0 | 392M |
| Common Stock Issued | 78.94M | 0 | 379.76M | 380.98M | 86M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 39.61M | 501.21M | 8.39M | 18.26M | 0 |
| Financing Cash Flow | 118.55M | 501.21M | 388.14M | 399.24M | 478M |
| Effect of Forex Changes | (1.19M) | (1.08M) | 462K | (2.53M) | 5.47M |
| Net Change in Cash | (416.71M) | (171.98M) | 81.8M | (35.24M) | 253.47M |
| Free Cash Flow | (411.79M) | (526.59M) | (521.57M) | (421.68M) | (472M) |
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
Intrinsic Alpha fair value
Locked
Current Price
$17.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.